Peter Elliott

Peter Elliott, Ph.D., is a Scientific Advisor at Jupiter Neurosciences, Inc. Mr. Elliott holds a B.Sc. in Pharmacology from London University and a Ph.D. in Psychopharmacology from Cambridge University, After post-docs at Duke, Yale and McGill, Mr. Elliott moved back to the UK to join Glaxo Group Research. During his 5 years there he led a number of CNS programs focusing on movement disorders, neurodegeneration as well as pain. Peter moved back to the USA to enter biotech at Alkermes in Cambridge, MA, as Director of Pharmacology. After that he moved on to ProScript which was acquired by LeukoSite, and ultimately Millennium. Mr. Elliott was Vice President of Pharmacology and Development during this time and was a co-developer of the multiple myeloma drug, Velcade© and PS-519 for stroke. He later moved on to join CominatoRx where he was Executive Vice President of Product Development and led the efforts resulting in 8 phase II programs in inflammation and oncology. Peter was then Senior Vice President of R&D at Sirtris Pharmaceuticals. As part of work from his teams, three SIRT1 activators entered clinical development, SRT501, SRT2104 and SRT2379. He was also an integral part of the road-show to take Sirtris public with a successful IPO in 2007, leading to it being purchased by GSK in 2008 for $720M. Subsequently, Peter has acted as a consultant to the industry.